TFEB and cancer: In cancer cells, suberoylanilide hydroxamic acid (SAHA), a well‐established HDAC inhibitor, promotes acetylation of TFEB at K91, K103, K116, and K430 by enhancing the interaction of acetyl‐coenzyme A acetyltransferase 1 (ACAT1) with TFEB.